Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse, mehr …
Heavy bleeding after giving birth is globally a leading cause of death in new mothers
Novo Nordisk today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, recommending an extension of the Novo Seven (eptacog alfa) label to include treatment of women suffering from severe haemorrhage after giving birth, when medications used to induce uterine contractions and reduce bleeding (uterotonics) are insufficient to stop the bleeding, mehr …
Planta Corps Eigenmarke Acti Novo liefert Gesundheit mit dem Versprechen von Qualität
Schnelle, hochwertige Umsetzung der Produkte »Made in Germany«, mehr …
Novo Nordisk A/S: Share repurchase programme
On 2 February 2022, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the “Safe Harbour Rules”), mehr …
Novo Nordisk A/S, Share Repurchase Programme
On 3 May 2022, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the “Safe Harbour Rules”), mehr …
Cheerwine Announces Return of Cheerwine Holiday Punch; Launches Cheerwine Holiday Ale in Collaboration With “NoDa” Brewing Company
The N.C. family owned #beverage brands deepen partnership with new seasonal offering, mehr …
Novo Nordisk to Expand R & D Presence in Greater Boston Area
Novo Nordisk just announced plans to expand its research and development (R & D) presence in the greater Boston metro area, creating one of its largest R & D hubs outside of Denmark, mehr …
Novo Nordisk A/S, Share repurchase programme
On 5 November 2021, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the “Safe Harbour Rules”), mehr …
Novo Nordisk A/S, Share repurchase programme
This programme is part of the overall share repurchase programme of up to DKK 20 billion to be executed during a 12-month period beginning 3 February 2021, mehr …
Novo Nordisk achieves primary objectives of Onwards 1 and 6 trials
Novo Nordisk today announced headline results from the main phases of Onwards 1 (52 weeks) and Onwards 6 (26 weeks) phase 3a trials with once-weekly insulin icodec, mehr …
Heartseed and Novo Nordisk announce first patient dosed in clinical study with HS-001—a cell therapy designed to restore heart function in people with advanced heart failure
HS 001 consists of clusters of purified heart muscle cells derived from induced pluripotent stem cells (iPSCs), mehr …
Novo Nordisk expands research collaboration in novel delivery technologies for biologic medicines
Novo Nordisk today announced the expansion of its existing research collaboration in oral drug delivery technologies with the Massachusetts Institute of Technology (MIT) and Brigham and Women’s Hospital (BWH), mehr …
Novo Nordisk – major shareholder announcement
Novo Nordisk today announced that the company has been notified by BlackRock, Inc. (Blackrock) that Blackrock as of 8 March 2022 holds B shares equal to below 5% of the entire share capital of Novo Nordisk. The announcement is in accordance with section 30 of the Danish Capital Markets Act, mehr …
Novo Nordisk—major shareholder announcement
Novo Nordisk today announced that the company has been notified by Black Rock, Inc. (Blackrock) that Blackrock as of 31 May 2022 holds B shares equal to below 5 percent of the entire share capital of Novo Nordisk. The announcement is in accordance with section 30 of the Danish Capital Markets Act, mehr …
Once-weekly insulin icodec demonstrates superior reduction in HbA1c
Mehr …
Novo Nordisk – major shareholder announcement
Novo Nordisk today announced that the company has been notified by BlackRock, Inc. (Blackrock) that Blackrock as of 8 February 2022 holds B shares equal to 5.05% of the entire share capital of Novo Nordisk. The announcement is in accordance with section 30 of the Danish Capital Markets Act, mehr …
Novo Nordisk A/S, Share repurchase programme
The execution of Novo Nordisk A/S’ overall share repurchase programme for 2022 of DKK 24 billion continues, mehr …
Novo Nordisk invests DKK 5.4 bn Danish kroner in expansion of clinical manufacturing facilities in Bagsværd, Denmark
Novo Nordisk today announced plans to invest 5.4 bn Danish kroner in the expansion of existing facilities in Bagsværd. The plans also include the construction of a new plant located in extension of the existing facilities, mehr …
»ApoRisk«: Apotheken Nachrichten vom 18. Dezember 2023 – Update
»Entdecken Sie die dynamische Entwicklung, wegweisende Forschung und die bedeutendsten Herausforderungen, die die Apothekenlandschaft prägen.«, mehr …
Gripen E now in Operation with Brazilian Air Force
The Brazilian Air Force (FAB) held a ceremony on December 19th at the Anápolis Air Base (BAAN) marking the beginning of operational activities of the Gripen E fighters (referred to as Gripen F-39 in Brazil) by the First Air Defense Group (1st GDA), mehr …
Deal approved without restrictions by CADE, Brazil’s antitrust body; acquisition accelerates Taste Elevation strategy in a priority growth market for Kraft Heinz
The Kraft Heinz Company (Nasdaq: KHC) (“Kraft Heinz”), the owner of the Heinz and Quero brands in Brazil, announced today that it completed its acquisition of a majority stake in Companhia Hemmer Indústria e Comércio (“Hemmer”), a Brazilian food company focused on condiments and sauces, after the deal was approved without restriction by CADE (Brazil’s Administrative Council for Economic Defense), Brazil’s antitrust body. The proposed deal was announced in September 2021, and CADE was notified in November 2021, mehr …
GB Sciences Signs Licensing Deal With «EndoPure« Life Sciences for 5 Percent Gross Sales Royalty & Sponsorship of First in Human Trial for Their Cannabinoid Based Parkinson’s Drug
As a part of their Exclusive Licensing Deal, “EndoPure” Life Sciences will finance and sponsor first in human clinical trials, which help to advance GB Sciences’ cannabinoid based products globally, mehr …
Ein Sommer voller WM Begeisterung startet in San Diego
Von Fan Zonen am Strand über Public Viewing in der Nachbarschaft bis hin zu Themen Events – hier kann das globale Turniergeschehen verfolgt werden, mehr …
The First Serial Production Gripen E Fighters are in Brazil
The first two serial production Gripen E fighters, called F-39 Gripen by the Brazilian Air Force (FAB), are in Brazil. The aircraft arrived in the country last Friday, April 1st, at the port of Navegantes, and today completed their first flight in the country. The two aircraft flew from Navegantes International Airport to the Gripen Flight Test Center at the Embraer plant in Gavião Peixoto, mehr …
Novo Nordisk files annual report with the SEC
Novo Nordisk A/S has filed its Annual Report 2021 on Form 20-F for the financial year 2021 with the US Securities and Exchange Commission (SEC), incorporating by reference parts of the Novo Nordisk A/S Annual Report 2021, mehr …
